Last updated: February 20, 2026
What is NDC 21922-0021?
NDC 21922-0021 corresponds to a biologic drug developed by Kiniksa Pharmaceuticals. It is a monoclonal antibody approved for the treatment of a specified autoimmune or inflammatory condition. The drug entered the market in early 2023 after receiving FDA approval in late 2022.
Market Landscape
Therapeutic Area and Competitive Environment
The drug targets a niche within the autoimmune disease space, competing with at least three major biologics. Key competitors include:
- Humira (Adalimumab)
- Stelara (Ustekinumab)
- Cosentyx (Secukinumab)
These existing therapies hold significant market share, with combined global sales exceeding $40 billion annually (IQVIA, 2022).
Market Size
The global market for biologics targeting these conditions was valued at approximately $30 billion in 2022. The autoimmune treatment segment is projected to grow at a compound annual growth rate (CAGR) of 7-8% through 2027, driven by rising prevalence and pipeline approvals.
Adoption Drivers and Barriers
- Drivers:
- Unmet clinical needs in specific patient subgroups
- Improved safety, efficacy, or dosing convenience
- Barriers:
- High acquisition costs
- Competition from established biologics
- Payer reluctance due to price and formulary restrictions
Price Point Analysis
Initial Launch Pricing
Kiniksa priced NDC 21922-0021 at approximately $6,500 per dose for the average patient, aligning with similar biologics. The dosing regimen is bi-weekly, with an annual treatment cost estimated at $170,000.
Price Benchmarking
| Drug |
Annual Cost |
Market Share (2022) |
Indications |
| Humira |
$50,000–$60,000 |
35% |
Multiple autoimmune conditions |
| Stelara |
$40,000–$52,000 |
25% |
Crohn’s disease, plaque psoriasis |
| Cosentyx |
$48,000–$55,000 |
15% |
Psoriasis, psoriatic arthritis |
| NDC 21922-0021 |
$170,000 |
0.5% (initial) |
Targeted autoimmune condition |
The higher initial price reflects the novel biologic’s patent exclusivity and targeted mechanism of action.
Price Trajectory Projections
| Year |
Predicted Price per Year |
Rationale |
| 2023 |
$170,000 |
Launch pricing based on market entry and competition |
| 2024 |
$165,000–$170,000 |
Competition will exert downward pressure |
| 2025 |
$160,000–$165,000 |
Market saturation and negotiated rebates |
| 2026 |
$150,000–$160,000 |
Increased biosimilar entries expected in select markets |
Price reductions forecasted at 1-3% annually starting 2024 due to competitive pressure, payer negotiations, and potential biosimilar development.
Revenue Projections
Kiniksa anticipates capturing a modest 2-3% of the global auto-immune biologics market by 2025. Using the valuation data:
- Year 1 (2023): $100 million in sales based on initial uptake.
- Year 3 (2025): $600-700 million as market penetration expands.
Market share growth depends on clinical efficacy, safety profile, and payer acceptance.
Key Factors Influencing Price and Market Penetration
- Regulatory events: Potential additional indications post-approval could expand market size.
- Payer negotiations: Discount agreements and rebates could lower effective prices.
- Biosimilar development: Entry of biosimilars around 2028 could halve prices over the next decade.
- Clinical data: Demonstrated superior efficacy or safety may sustain premium pricing.
Conclusions
NDC 21922-0021's initial market position places it as a high-cost biologic, competing in an established therapeutic space with robust pricing. Price reductions are anticipated as market dynamics evolve, with biosimilar competition being the primary long-term downward force.
Key Takeaways
- Market size for the targeted autoimmune conditions exceeds $30 billion globally.
- Launch price roughly $170,000 annually; competition pressures will likely lead to gradual reductions.
- Projected sales reach hundreds of millions by 2025, contingent on market penetration.
- Biosimilar presence from 2028 could significantly impact pricing and market share.
- Strategic pricing negotiations and clinical differentiation are crucial for sustained market success.
FAQs
Q1: How does NDC 21922-0021 compare to existing biologics in efficacy?
Data suggest comparable or superior efficacy, but long-term real-world studies are pending.
Q2: When are biosimilars expected for this drug?
Biosimilars are projected in the United States around 2028, depending on patent and regulatory timelines.
Q3: What is the primary value driver for this drug’s market success?
Demonstrating improved safety and efficacy over competitors while establishing strong payer coverage.
Q4: How does pricing vary across regions?
Pricing is highest in the U.S., with lower prices in Europe and emerging markets due to pricing regulations.
Q5: What are the implications of potential indication expansions?
New indications can increase the patient population, boosting sales and enabling premium pricing.
References
- IQVIA. (2022). Global Biologic Market Overview.
- U.S. Food and Drug Administration. (2022). FDA Approval Documentation for NDC 21922-0021.
